article thumbnail

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

Drug Channels

Each exclusion list now contains about 600 products. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.

Insulin 92
article thumbnail

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars (rerun)

Drug Channels

Each exclusion list now contains about 600 products. Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira.

Insulin 95
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Soliqua® data shows improved blood sugar control without weight gain versus premixed insulin

The Pharma Data

New Soliqua ® * data shows improved blood sugar control without weight gain versus premixed insulin. Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin.

Insulin 52
article thumbnail

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes | Eli Lilly and Company

The Pharma Data

The Tempo Pen is a modified version of Lilly ‘s existing prefilled, disposable insulin pen to which the Tempo Smart Button – pending CE (Conformité Européenne or European Conformity) marking – attaches. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin. About DexCom Inc.

Insulin 52
article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the US, impacted by prior formulary losses as well as “erosion of the basal insulin market,” the company said in the statement. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6

Sales 52
article thumbnail

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions

Drug Channels

Each exclusion list contains 400 to 500 products. Below, I highlight five observations about this year’s lists, including unexplainable differences in how PBMs handle specialty drugs, biosimilars, and insulin. I also offer some thoughts on non-medical switching and what we still don’t know about how exclusions affect patients.

Insulin 94
article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

One of these markets is the insulin market. Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. Currently, more than seven million patients rely on insulin, and that number is growing each year. But, that will soon be changing, due to biosimilars.